Items without sitelinks

Jump to navigation Jump to search

Showing below up to 50 results starting with #5,751.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Table 2 - Expected Number of Symptomatic SARS-CoV-2 Infections That Would Be Undetected During Active Monitoring, Given Varying Monitoring Durations and Risks for Symptomatic Infection After Exposure* (From DOI: 10.7326/m20-0504) (Q7929)
  2. Table 1 - Characteristics of Patients With Confirmed COVID-19 Included in This Analysis (n = 181)* (From DOI: 10.7326/m20-0504) (Q7928)
  3. Discussion (Main section from DOI: 10.7326/m20-0504) (Q7927)
  4. Results (Main section from DOI: 10.7326/m20-0504) (Q7926)
  5. Methods: Role of the Funding Source (Subsection from DOI: 10.7326/m20-0504) (Q7925)
  6. Methods: Statistical Analysis (Subsection from DOI: 10.7326/m20-0504) (Q7924)
  7. Methods: Data Collection (Subsection from DOI: 10.7326/m20-0504) (Q7923)
  8. Introduction (Main section from DOI: 10.7326/m20-0504) (Q7922)
  9. Appendix in Publication (Q7921)
  10. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application (DOI: 10.7326/m20-0504) (Q7920)
  11. Developing vaccines against epidemic-prone emerging infectious diseases (DOI: 10.1007/s00103-019-03061-2) (Q7919)
  12. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies (DOI: 10.3390/v12030254) (Q7918)
  13. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review (DOI: 10.3390/pathogens9020148) (Q7917)
  14. Bibliography Entry in a Publication (Q7916)
  15. License Statement (From DOI: 10.3390/pathogens9020148) (Q7915)
  16. License Statement (Q7914)
  17. Full Bibliography (From DOI: 10.3390/pathogens9020148) (Q7913)
  18. Conflicts of Interest (From DOI: 10.3390/pathogens9020148) (Q7912)
  19. Acknowledgments (From DOI: 10.3390/pathogens9020148) (Q7911)
  20. Author Contributions (From DOI: 10.3390/pathogens9020148) (Q7910)
  21. Table 2 - Examples of recombinant antigens and monoclonal antibodies expressed in plants (From DOI: 10.3390/pathogens9020148) (Q7909)
  22. Table 1 - Advantages and disadvantages of different therapeutic protein production platforms (From DOI: 10.3390/pathogens9020148) (Q7908)
  23. Concluding Remarks section from DOI: 10.3390/pathogens9020148 (Q7907)
  24. Perspectives on Biopharmaceuticals Development section from DOI: 10.3390/pathogens9020148 (Q7906)
  25. Transmission and Symptoms section from DOI: 10.3390/pathogens9020148 (Q7905)
  26. Novel Coronavirus 2019-nCoV section from DOI: 10.3390/pathogens9020148 (Q7904)
  27. 9th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7888)
  28. 8th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7887)
  29. 7th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7886)
  30. 6th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7885)
  31. 5th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7884)
  32. 4th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7883)
  33. 3rd paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7882)
  34. 2nd paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7881)
  35. 1st paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7880)
  36. 6th paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7879)
  37. 5th paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7878)
  38. 4th paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7877)
  39. 3rd paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7876)
  40. 2nd paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7875)
  41. 1st paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7874)
  42. 2nd paragraph(s) in Results: Mapping the SARS-CoV-Derived T Cell Epitopes That Are Identical in SARS-CoV-2, and Determining Those with Greatest Estimated Population Coverage section (From DOI: 10.3390/v12030254) (Q7873)
  43. 1st paragraph(s) in Results: Mapping the SARS-CoV-Derived T Cell Epitopes That Are Identical in SARS-CoV-2, and Determining Those with Greatest Estimated Population Coverage section (From DOI: 10.3390/v12030254) (Q7872)
  44. 2nd paragraph(s) in Results: Structural Proteins of SARS-CoV-2 Are Genetically Similar to SARS-CoV, but Not to MERS-CoV section (From DOI: 10.3390/v12030254) (Q7871)
  45. 1st paragraph(s) in Results: Structural Proteins of SARS-CoV-2 Are Genetically Similar to SARS-CoV, but Not to MERS-CoV section (From DOI: 10.3390/v12030254) (Q7870)
  46. 1st paragraph(s) in Materials and Methods: Data and Code Availability section (From DOI: 10.3390/v12030254) (Q7869)
  47. 1st paragraph(s) in Materials and Methods: Constructing the Phylogenetic Tree section (From DOI: 10.3390/v12030254) (Q7868)
  48. 1st paragraph(s) in Materials and Methods: Population-Coverage-Based T Cell Epitope Selection section (From DOI: 10.3390/v12030254) (Q7867)
  49. 1st paragraph(s) in Materials and Methods: Acquisition and Filtering of Epitope Data section (From DOI: 10.3390/v12030254) (Q7866)
  50. 1st paragraph(s) in Materials and Methods: Acquisition and Processing of Sequence Data section (From DOI: 10.3390/v12030254) (Q7865)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:ItemsWithoutSitelinks"